Results 61 to 70 of about 2,763 (183)

Efficacy, tolerability, and safety of erenumab for the preventive treatment of persistent post-traumatic headache attributed to mild traumatic brain injury: an open-label study

The Journal of Headache and Pain, 2020
Background Calcitonin gene-related peptide (CGRP) has recently been implicated in the pathogenesis of post-traumatic headache (PTH), which raises the prospect for therapeutic use of monoclonal antibodies targeting CGRP or its receptor.
Håkan Ashina, Afrim Iljazi, Haidar Muhsen Al-Khazali, Anna Kristina Eigenbrodt, Eigil Lindekilde Larsen, Amalie Middelboe Andersen, Kevin John Hansen, Karoline Bendix Bräuner, Thomas Mørch-Jessen, Basit Chaudhry, Sonja Antic, Casper Emil Christensen, Messoud Ashina, Faisal Mohammad Amin, Henrik Winther Schytz   +14 more
doaj   +1 more source

A systematic review of economic evaluations of pharmacological treatments for adults with chronic migraine

The Journal of Headache and Pain, 2022
Background and aims Chronic migraine is a common neurovascular brain disorder with substantial economic costs. We performed a systematic review to identify economic evaluations of pharmacological treatments for adults with chronic migraine.
Saval Khanal, Martin Underwood, Seyran Naghdi, Anna Brown, Callum Duncan, Manjit Matharu, Hema Mistry   +6 more
doaj   +1 more source

Long-term efficacy and safety of erenumab in Japanese patients with episodic and chronic migraine: results from a 28-week open-label treatment period of a randomised trial

BMJ Open, 2023
Objectives To evaluate the 1-year efficacy and safety of once-monthly erenumab 70 mg following a 24-week double-blind treatment period (DBTP) of a phase III randomised study of Japanese patients with episodic migraine (EM) or chronic migraine (CM).Design
Koichi Hirata, Fumihiko Sakai, Miki Hasebe, Takao Takeshima, Yotaro Numachi, Ryuji Yoshida, Reija Koukakis, Daishi Yui, Gabriel Paiva da Silva Lima, Sunfa Cheng   +9 more
doaj   +1 more source

MAB-MIG: Registry of the Spanish Neurological Society of erenumab for migraine prevention [PDF]

, 2021
Erenumab was approved in Europe for migraine prevention in patients with ≥ 4 monthly migraine days (MMDs). In Spain, Novartis started a personalized managed access program, which allowed free access to erenumab before official reimbursement.
Jurado, Carmen, Belvís, Robert, Cuadrado, Elisa, González Oria, carmen, Toledano, Carlos, Oterino, Agustín, Molina, Francisco, Ezpeleta, David, Morollón, Noemí, Oms, Teresa, Alberte-Woodward, Miguel, Cano, Antonio, Viguera, Javier, Gómez-Camello, Angel, Torres-Ferrús, Marta, Lamas, Raquel, Santos, Sonia, Sánchez del Río, Margarita, Beltrán, Isabel, Latorre, Germán, Irimia, Pablo, Alpuente, Alicia, Pozo-Rosich, Patricia, Leira, Rogelio, Sánchez, Belén, de Terán, Javier Díaz   +25 more
core   +1 more source

Lack of Differences in the Pharmacokinetics of Therapeutic Monoclonal Antibodies Between Japanese and Non‐Japanese Individuals

The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Evaluation of the pharmacokinetics (PK) of new drugs in Japanese individuals is regularly requested by the Japanese regulatory agency prior to participation in global clinical trials or for bridging approaches for regulatory approval. However, the need for PK assessments in the Japanese population may be less compelling for monoclonal ...
Paridhi Gupta, Ashish Sharma, Bernd Meibohm   +2 more
wiley   +1 more source

Erenumab does not alter cerebral hemodynamics and endothelial function in migraine without aura

, 2020
Objective: To assess whether erenumab influences cerebral vasomotor reactivity and flow-mediated dilation in migraine patients.Methods: Consecutive migraineurs prescribed erenumab at our Headache Centre and age and sex-matching controls were invited to ...
Silvestrini, Mauro, Vernieri, Fabrizio, Altamura, Claudia, Viticchi, Giovanna, Fallacara, Adriana, Costa, Carmelina Maria, Fiori, Chiara, Brunelli, Nicoletta   +7 more
core   +1 more source

Does erenumab reduce monthly migraine frequency from baseline in adults with episodic migraines? [PDF]

, 2023
OBJECTIVE: The objective of this selective EBM review is to determine “Does erenumab reduce monthly migraine frequency from baseline in adults with episodic migraines?” STUDY DESIGN: An EBM review of three double blind, RCTs (randomized control trials ...
Pitman, Rachel M.
core   +1 more source

Timing and durability of response to erenumab in patients with chronic migraine

, 2021
Background: Erenumab is a human anti-calcitonin gene-related peptide receptor monoclonal antibody approved for migraine prevention. We sought to further assess the temporal patterns of response to erenumab in patients with chronic migraine (CM ...
Jessica Ailani, Denise E. Chou, Ailani, Jessica, Jan Klatt, Sylvia Lucas, Andrea Wang, Paiva da Silva Lima, Gabriel, Wang, Andrea, Stewart J. Tepper, Klatt, Jan, Gabriel Paiva da Silva Lima, Ashina, Messoud, Schwedt, Todd J., Chou, Denise E., Lucas, Sylvia, Todd J. Schwedt, Tepper, Stewart J., Messoud Ashina, Scanlon, James, James Scanlon   +19 more
core   +1 more source

Effectiveness of galcanezumab versus topiramate, amitriptyline, and other select traditional oral migraine preventives with evidence of efficacy: 3‐Month results from the TRIUMPH study

Headache: The Journal of Head and Face Pain, Volume 66, Issue 7, Page 1525-1536, July/August 2026.
Abstract Objective To compare the 3‐month effectiveness of galcanezumab with select traditional oral migraine preventive (TOMP) medications recommended by scientific societies (TOMP efficacy subset) and with the most frequently used individual TOMP medications.
Shivang Joshi, Cristina Tassorelli, Manjit Matharu, Taoufik Alsaadi, Carlos Vallarino, Lars Viktrup, Maurice Vincent, Rebecca L. Robinson   +7 more
wiley   +1 more source

Pharmacokinetics and safety of erenumab in pediatric patients with migraine: A phase I, randomized, open‐label, multiple‐dose study

Clinical and Translational Science
Erenumab, a fully human monoclonal antibody targeting the calcitonin gene‐related peptide receptor, is efficacious and safe for prevention of attacks of migraine in adults.
Andrew D. Hershey, Gabriel Paiva da Silva Lima, Nicola Pannacciulli, Mia Mackowski, Reija Koukakis, Jennifer Williams McVige   +5 more
doaj   +1 more source